Co-Diagnostics Statistics
Total Valuation
Co-Diagnostics has a market cap or net worth of $37.65 million. The enterprise value is -$3.69 million.
Important Dates
The next confirmed earnings date is Thursday, November 7, 2024, after market close.
| Earnings Date | Nov 7, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Co-Diagnostics has 31.91 million shares outstanding. The number of shares has decreased by -0.57% in one year.
| Current Share Class | 31.91M |
| Shares Outstanding | 31.91M |
| Shares Change (YoY) | -0.57% |
| Shares Change (QoQ) | +0.94% |
| Owned by Insiders (%) | 5.40% |
| Owned by Institutions (%) | 14.73% |
| Float | 30.19M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.93 |
| Forward PS | 71.56 |
| PB Ratio | 0.53 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.09, with a Debt / Equity ratio of 0.04.
| Current Ratio | 9.09 |
| Quick Ratio | 8.56 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -42.73% and return on invested capital (ROIC) is -26.63%.
| Return on Equity (ROE) | -42.73% |
| Return on Assets (ROA) | -25.00% |
| Return on Capital (ROIC) | -26.63% |
| Revenue Per Employee | $58,948 |
| Profits Per Employee | -$242,387 |
| Employee Count | 155 |
| Asset Turnover | 0.09 |
| Inventory Turnover | 1.19 |
Taxes
In the past 12 months, Co-Diagnostics has paid $1.76 million in taxes.
| Income Tax | 1.76M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -0.82% in the last 52 weeks. The beta is -0.85, so Co-Diagnostics's price volatility has been lower than the market average.
| Beta (5Y) | -0.85 |
| 52-Week Price Change | -0.82% |
| 50-Day Moving Average | 1.26 |
| 200-Day Moving Average | 1.23 |
| Relative Strength Index (RSI) | 44.57 |
| Average Volume (20 Days) | 62,912 |
Short Selling Information
The latest short interest is 226,426, so 0.71% of the outstanding shares have been sold short.
| Short Interest | 226,426 |
| Short Previous Month | 205,289 |
| Short % of Shares Out | 0.71% |
| Short % of Float | 0.75% |
| Short Ratio (days to cover) | 2.58 |
Income Statement
In the last 12 months, Co-Diagnostics had revenue of $9.14 million and -$37.57 million in losses. Loss per share was -$1.27.
| Revenue | 9.14M |
| Gross Profit | 5.47M |
| Operating Income | -38.70M |
| Pretax Income | -35.81M |
| Net Income | -37.57M |
| EBITDA | -37.42M |
| EBIT | -38.70M |
| Loss Per Share | -$1.27 |
Full Income StatementBalance Sheet
The company has $44.88 million in cash and $2.58 million in debt, giving a net cash position of $42.30 million or $1.33 per share.
| Cash & Cash Equivalents | 44.88M |
| Total Debt | 2.58M |
| Net Cash | 42.30M |
| Net Cash Per Share | $1.33 |
| Equity (Book Value) | 72.40M |
| Book Value Per Share | 2.27 |
| Working Capital | 42.91M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$24.24 million and capital expenditures -$1.20 million, giving a free cash flow of -$25.44 million.
| Operating Cash Flow | -24.24M |
| Capital Expenditures | -1.20M |
| Free Cash Flow | -25.44M |
| FCF Per Share | -$0.80 |
Full Cash Flow StatementMargins
| Gross Margin | 59.83% |
| Operating Margin | -423.56% |
| Pretax Margin | -391.88% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -287.51% |
Dividends & Yields
Co-Diagnostics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.57% |
| Shareholder Yield | 0.57% |
| Earnings Yield | -98.05% |
| FCF Yield | -66.39% |
Analyst Forecast
The average price target for Co-Diagnostics is $1.50, which is 27.12% higher than the current price. The consensus rating is "Hold".
| Price Target | $1.50 |
| Price Target Difference | 27.12% |
| Analyst Consensus | Hold |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Co-Diagnostics has an Altman Z-Score of 1.66 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.66 |
| Piotroski F-Score | 2 |